NBIX – neurocrine biosciences, inc. (US:NASDAQ)
Stock Stats
News
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy [Yahoo! Finance]
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at HC Wainwright from $168.00 to $198.00. They now have a "buy" rating on the stock.
Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript [Seeking Alpha]
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology [Yahoo! Finance]
Form 4 NEUROCRINE BIOSCIENCES For: Dec 15 Filed by: Norwalk Leslie V
Form 144 NEUROCRINE BIOSCIENCES Filed by: Norwalk Leslie V
Form 4 NEUROCRINE BIOSCIENCES For: Dec 08 Filed by: Lippoldt Darin
Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin
Form 4 NEUROCRINE BIOSCIENCES For: Dec 03 Filed by: LYONS GARY A
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.